Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

Hong Kong-based Akeso has announced that the US Food and Drug Administration (FDA) has approved its PD-1 monoclonal antibody, penpulimab-kcqx, alongside cisplatin or carboplatin and gemcitabine, for ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

AKESO (09926.HK) sank to a bottom of $84.1. It last traded at $84.1, down 14.96%, on a volume of 1.254 million shares and a ...

As trade tensions between the U.S. and China show signs of easing, Asian markets are experiencing a renewed sense of optimism, particularly in the technology sector where growth prospects remain ...

There was HKD2 billion, HKD779 million and HKD556.9 million Southbound Trading net inflow to TRACKER FUND (02800.HK), AKESO ...

Summit Therapeutics Inc.’s SMMT share price has surged by 6.58%, which has investors questioning if this is right time to ...

ET Net News Agency, 28 April 2025] Nomura raised the target price for Akeso (09926) to HKD99.66 from HKD75.14 and downgraded the rating to "neutral" from "buy". The research hous ...